Aqualung Therapeutics, Corp
Juno Beach, FL Aqualung Therapeutics, Corp
- UEI
- MKDKZ3ZZ99A2
- CAGE
- 80NH5
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 450 Ocean Dr #1205, Juno Beach, FL 33408, USA
- Website
- aqualungtherapeutics.com
- Founded
- 2010
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Aqualung Therapeutics, Corp
Aqualung Therapeutics, Corp is a minority-owned, for-profit corporate entity registered in SAM.gov, located in Juno Beach, Florida, with an active registration through May 2026. The company appears to be a biotechnology research organization focused on developing novel monoclonal antibody therapies targeting inflammatory and fibrotic disease pathways. While specific details about the company's full portfolio are not provided, their federal grant award history suggests a specialized focus on developing therapeutic interventions for complex respiratory and inflammatory conditions.
The company has secured multiple federal grants from prestigious national institutes, including the National Institute of Allergy and Infectious Diseases, National Heart Lung and Blood Institute, and National Institute of Diabetes and Digestive and Kidney Diseases. Their research has concentrated on developing a humanized monoclonal antibody (ALT-100) that targets the ENAMPT-TLR4 signaling pathway to address serious medical conditions such as idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), inflammatory bowel disease, and pulmonary hypertension. In collaboration with Quell Pharma, they have been developing innovative therapeutic approaches like the tandem P-selectin glycoprotein ligand-1 immunoglobulin (TSGL-IG) to inhibit leukocyte adhesion and reduce systemic inflammation. Their grant-funded research involves preclinical studies using mouse and rat models to optimize dosing, evaluate efficacy, and assess potential therapeutic windows for their investigational treatments across multiple disease states.
Quick answers
What is Aqualung Therapeutics, Corp's UEI?
Aqualung Therapeutics, Corp's Unique Entity ID (UEI) in SAM.gov is MKDKZ3ZZ99A2.
What is Aqualung Therapeutics, Corp's CAGE code?
Aqualung Therapeutics, Corp's CAGE code is 80NH5.
Where is Aqualung Therapeutics, Corp located?
Aqualung Therapeutics, Corp's physical address in SAM.gov is 450 Ocean Dr #1205, Juno Beach, FL 33408, USA.
Is Aqualung Therapeutics, Corp registered in SAM.gov?
Yes. Aqualung Therapeutics, Corp's SAM.gov registration is active through April 22, 2027.
What is Aqualung Therapeutics, Corp's most recent federal award?
Aqualung Therapeutics, Corp's most recent federal grant award is Targeting enampt-TLR4 signaling with the novel ALT-100 MAB to slow IPF progression - abstract: there is a major unmet… (R41HL180035), from National Heart Lung and Blood Institute, on September 20, 2025.
On GovTribe
See Aqualung Therapeutics, Corp's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors